Research Article

Experience Reduces Surgical and Hardware-Related Complications of Deep Brain Stimulation Surgery: A Single-Center Study of 181 Patients Operated in Six Years

Mehmet Sorar, 1 Sahin Hanalioglu, 1 Bilge Kocer, 2 Muhammed Taha Eser, 1 Selim Selcuk Comoglu, 2 and Hayri Kertmen 1

1Department of Neurosurgery, Diskapi Yildirim Beyazit Training and Research Hospital, Health Sciences University, Ankara, Turkey
2Department of Neurology, Diskapi Yildirim Beyazit Training and Research Hospital, Health Sciences University, Ankara, Turkey

Correspondence should be addressed to Hayri Kertmen; hayri_kertmen@yahoo.com

Received 29 January 2018; Accepted 23 May 2018; Published 22 July 2018

Objective. Deep brain stimulation (DBS) surgery has increasingly been performed for the treatment of movement disorders and is associated with a wide array of complications. We aimed to present our experience and discuss strategies to minimize adverse events in light of this contemporary series and others in the literature.

Methods. A retrospective chart review was conducted to collect data on age, sex, indication, operation date, surgical technique, and perioperative and late complications.

Results. A total of 181 patients (113 males, 68 females) underwent DBS implantation surgery (359 leads) in the past six years. Indications and targets were as follows: Parkinson’s disease (STN) (n = 159), dystonia (GPi) (n = 13), and essential tremor (Vim) (n = 9). Mean age was 55.2 ± 11.7 (range 9–74) years. Mean follow-up duration was 3.4 ± 1.6 years. No mortality or permanent morbidity was observed. Major perioperative complications were confusion (6.6%), intracerebral hemorrhage (2.2%), stroke (1.1%), and seizures (1.1%). Long-term adverse events included wound (7.2%), mostly infection, and hardware-related (5.5%) complications. Among several factors, only surgical experience was found to be related with overall complication rates (early period: 31% versus late period: 10%; p = 0.001).

Conclusion. The rates of both early and late complications of DBS surgery are acceptably low and decrease significantly with cumulative experience.

1. Introduction

Since its introduction in 1987, deep brain stimulation (DBS) has become an effective treatment modality in the management of movement disorders [1, 2]. Clinical trials have proven its efficacy in Parkinson’s disease (PD) and other hyperkinetic diseases [2–4]. In recent years, its indications have been broadened by successful applications in many other neuropsychiatric disorders [5].

As in all surgical operations, this procedure is not without complications and problems. In addition to operative complications, inherent to the technique are hardware- and stimulation-related adverse events, which have increasingly been recognized in the literature as the experience has exponentially grown in the past years [6–10]. Here, we present our experience with 181 patients undergoing DBS placement and discuss strategies to minimize complications and adverse events in the light of this contemporary series and others in the literature.

2. Materials and Methods

2.1. Patients. All patients who had undergone DBS implantation surgery at Diskapi Yildirim Beyazit Training and Research Hospital between 2012 and 2017 were included in this retrospective study. Primary diagnoses and surgical targets were as follows: Parkinson’s disease (subthalamic nucleus (STN)), dystonia (globus pallidus interna (GPi)), and essential tremor (ET) (ventral intermediate nucleus of the thalamus (Vim)). All procedures were performed by the
2.3. Statistical Analysis. All statistical analyses were performed using the standard statistical software (SPSS Statistics, version 22.0; SPSS Inc.). Risk factors for the occurrence of adverse effects such as patient’s age, diagnosis, and date of surgery (early period: 2011−2014; late period: 2014−2017) were analyzed with logistic regression. Student’s t-test with equal variances was used to compare age at implantation between patients with adverse effects and those without. Evaluation of differences between patients with adverse events depending on surgical experience was performed using the Fisher exact test. A p value below 0.05 was considered as statistically significant.

3. Results

3.1. Demographic Data. One hundred eighty-one patients received 359 new DBS leads in a total of 181 stereotactic procedures. Two hundred and one IPG replacement procedures were performed during the study period. Of the newly implanted leads and IPGs, a majority (85%) were manufactured by St. Jude Medical and others by Medtronic.

One hundred fifty-nine patients suffered from PD, 13 from dystonia, and 9 from essential tremor. Targets were bilateral STN in all PD, bilateral Gpi in all dystonia, and bilateral Vim in all ET patients except for three cases in whom unilateral DBS implantation was done. Patients’ age ranged from 9 to 74 years (mean: 55.2 ± 11.7 years), and 62.4% were male. A vast majority of the patients (87.8%) had follow-up of more than 1 year (mean: 3.4 ± 1.6 years). No patients have been lost to follow-up.

3.2. Perioperative Events. A summary of perioperative and long-term complications is presented in Table 1. No mortality or permanent morbidity was observed after surgery in this series. Perioperative complications were detected in a total of 17 patients (9.4%). The most common perioperative adverse event was postoperative confusion/delirium, which was seen in 12 patients (6.6%). All these patients had PD and underwent bilateral STN DBS implantation. Confusion resolved in all patients with medication during hospitalization approximately within a week. Two patients (1.1%) had seizures in the early postoperative period and treated with a single antiepileptic drug (AED). They were seizure-free at the 6th month after surgery, and AED was discontinued.

The most common severe complication of surgery was hemorrhage (n = 5, 2.8%), including four cases of intracerebral hematoma (ICH) (2.2%) and one case of venous

| Complication/adverse event                  | Number | %  |
|--------------------------------------------|--------|----|
| Early perioperative complications (<30 days)|        |    |
| Confusion/alteration in mental status       | 12     | 6.6 |
| Hemorrhages                                 | 5      | 2.8 |
| Intracerebral hematoma                      | 4      | 2.2 |
| Asymptomatic                                | 2      | 1.1 |
| Symptomatic                                 | 2      | 1.1 |
| Venous hemorrhagic infarct                  | 1      | 0.6 |
| Ischemic infarct                            | 1      | 0.6 |
| Seizure                                    | 2      | 1.1 |
| Long-term complications (>30 days)         |        |    |
| Wound complications                         | 13     | 7.2 |
| Infection/dehiscence                        | 11     | 6.1 |
| Inflammation/allergy                        | 2      | 1.1 |
| Hardware-related complications              | 10     | 5.5 |
| Lead malposition/migration                  | 2      | 1.1 |
| Fracture/disconnection (lead or lead extension) | 8  | 4.4 |
| Other complications                         | 2      | 1.1 |
| Chronic subdural hematoma                   | 2      | 1.1 |
hemorrhagic stroke (0.6%). In two of them (1.1%), small hematomas along the leads were detected with no or only slight transient symptoms. However, one patient developed moderate paresis in both upper extremities (with a few hours interval) due to slowly evolving hemorraghes, possibly of venous origin, around both leads. The patient was treated conservatively and recovered completely in 6 months. In another patient, an ICH was suspected intraoperatively due to development of left hemiparesis following lead implantation. Immediate postoperative CT scan showed right caudate hematoma with associated intraventricular hemorrhage (Figures 1(a) and 1(b)). Then, the IPG placement was postponed, and the patient was transferred to the ICU where he was treated conservatively. One week later, his symptoms and hematoma largely resolved and he underwent IPG placement with no further problems.

Another patient developed slight right hemiparesis and dysphasia at postoperative day 3. She underwent CT scan which showed a left frontal venous hemorrhagic stroke (Figures 1(c) and 1(d)) evidenced by a relatively large infarct area around a small hemorrhagic component surrounding the lead. This patient recovered completely with no sequelae within 3 months.

One patient with essential tremor had ischemic stroke (0.6%). He became dysphasic immediately after the DBS implantation. Diffusion-weighted MRI showed acute diffusion restriction in the left frontal cortex around the electrode. He was also treated conservatively and recovered completely within a month.

3.3. Long-Term Events. Those events were described as adverse events that occurred later than 30 days after surgery. Wound and hardware complications constituted a majority of those problems.

3.3.1. Wound Complications. Infection was the most common wound complication (n = 11, 6.1%) followed by allergic inflammation (n = 2, 1.1%). A majority of those cases were self-limiting and managed with antibiotics. Four patients (2.2%) underwent surgery for debridement and repair of wound erosion and/or dehiscence without need for system removal. Scalp reconstruction was performed in two of them. Five patients (2.8%) required removal of the IPG due to infection or recurrent allergic inflammation at the IPG site. Two of them had infections due to trauma; two had abscess formation, and another had sterile seroma around the IPG. Revision surgery was performed depending on the system components affected (either IPG only or IPG + lead extensions).

3.3.2. Hardware Complications. Lead position was found to be suboptimal (>2 mm change from the initial position) in only two patients (1.1%) as confirmed by the comparison of late CT with early postoperative MRI and CT (fused images were used to identify the exact anatomic location of the leads). However, fracture or disconnection of leads or lead extensions (including component malfunction as indicated by high impedance in the system) was relatively common in this series (n = 8, 4.4%). In most cases (n = 7), the problem was detected in the lead extensions and only they were replaced. Twiddler’s syndrome was diagnosed in one of them. In one patient,iatrogenic injury to the DBS system (during an operation for a trauma in another center) resulted in the revision of the entire system including leads and extensions and IPG revision.

3.3.3. Other Complications and Problems. Two patients suffered from chronic subdural hematomas (cSDHs). One patient presented with speech disturbance and slight right-sided weakness 6 weeks after the DBS implantation. A CT scan showed a cSDH with multiple septations over the left hemisphere (Figure 1(e)). He underwent craniotomy to evacuate hematoma with preservation of DBS hardware (Figure 1(f)). He had an uneventful postoperative course and complete recovery. Another patient had a bilateral cSDH (more on the left than the right) following a mild head trauma 3 years after initial DBS surgery. He underwent an endoscope-assisted evacuation of the cSDH through burr holes, with preservation of DBS hardware. This patient also recovered completely.

3.4. Risk Factors. Potential predictors of adverse events were analyzed. Neither age nor sex was found to be related to risk of complications. Furthermore, there was not significant difference between age of the patients with and without complications (54.9 ± 9.9 versus 56.7 ± 9.3, p = 0.319). The primary diagnosis/indication, anatomical target, and device manufacturer did not appear to affect complication rates (20.1% versus 22.7%, p = 0.776), except for confusion occurring only in PD patients who underwent bilateral STN DBS. On the contrary, surgical experience seems to be directly related to overall complication rates (early period 2012–2014: 31.0% versus late period 2015–2017: 10.6%, p = 0.001). A drastic reduction in complication rates is observed throughout the years (Figure 2).

4. Discussion

Deep brain stimulation surgery has been utilized for the treatment of medically intractable movement disorders for more than two decades. Various clinical series have shown that it is a safe procedure with low rates of complications and adverse events, particularly in the experienced large-volume centers [8–10]. Here, we investigated occurrences and risk factors of surgical and hardware-related complications of DBS surgery performed by a single primary surgeon in a single center.

Early adverse events within 30 days of surgery are generally attributed to surgery [11, 12]. Literature regarding surgical complications in DBS surgery is extensive [6–16]. Incidences of overall short-term or surgery-related complications vary considerably between 2 and 20% depending largely on the definition of adverse events [12–14]. In our series, 11% of the patients experienced early complications. The most common surgical adverse event was perioperative
confusion (6.6%). Various studies have reported similar rates (3–7%) regarding postoperative mental status change, confusion, or delirium [9, 13, 15, 16]. It usually has a favorable course and resolves spontaneously or with adequate medication within a few days of hospitalization.

Seizures are also important complications of DBS surgery [17]. We had two patients (1.1%) having seizures following the hardware implantation. Their seizures were controlled with a single antiepileptic drug, which were discontinued 6 months after the operation. Some groups

Figure 1: Operative complications due to deep brain stimulation surgery. (a, b) Right caudate hematoma with intraventricular hemorrhage. (c) Venous hemorrhagic infarction around the left-sided DBS lead; (d) 6-month follow-up FLAIR MRI. (e, f) Pre- and postoperative images of the left-sided chronic subdural hematoma over the parietal cortex. Note that the frontal component of the cSDH was left intact to avoid iatrogenic injury to the lead.
have reported higher frequencies (4–7%) of postoperative seizures, nevertheless, in virtually all series; their outcomes were quite favorable posing no serious risk for DBS hardware or chronic epilepsy [17–19].

Although it is not very common, hemorrhagic events are the most feared ones of operative complications [20, 21]. Various large series reported incidences of hemorrhagic complications, mainly in the form of intracerebral hemorrhage, between 0.5 and 5% [8, 20–24]. Immediate postoperative imaging could miss an ICH as some ICHs develop or enlarge in delayed fashion [24]. Furthermore, more than half of ICHs are asymptomatic and usually require no intervention at all [8]. However, when large and symptomatic, ICH is one of the most dreadful complications of DBS surgery. Fortunately, such a symptomatic ICH is rarely encountered (<1-2%) and usually has a relatively benign course [6, 8, 25]. In our series, we observed two such cases (1.1%), both of whom recovered fully with medical treatment and observation only. On the contrary, we had to operate on a patient who presented with chronic subdural hematoma 1.5 months after the operation. Extensive membranes within the cSDH prevented us from doing minimally invasive drainage via burr holes [26]; therefore, we had to do craniotomy to evacuate hematoma while preserving the DBS system.

Stroke, both ischemic and hemorrhagic [27], is also a rare but serious complication after DBS implantation. We encountered one ischemic and one venous hemorrhagic infarct during the postoperative course. Both patients have eventually recovered with supportive medical treatment without necessitating hardware removal. Careful planning on preoperative images is a prerequisite for avoidance of vascular injury [23]. We routinely use TOF MRI in image fusion to track vascular structures, while other groups reported successful use of CT angiography [28], contrast-enhanced MRI [25], and SWI-MR venography [29] separately or in combination for this purpose. Whether microelectrode recording increases the risk of vascular injury is also a matter of debate [22, 23], with some groups reporting a significant drop in the rates of hemorrhagic complications after minimizing or refraining from microelectrode recording [21, 30]. Likewise, we usually perform MER with only two electrodes (between one and three), which could possibly reduce the risk of vascular injury in comparison to multiple microelectrode insertion techniques.

Late complications might be equally, or even more, problematic [31]. Wound complications, particularly infection, comprise the majority of these complications [32, 33]. A recent systematic review of hardware-related complications of DBS surgery revealed that infections (5.12%) were followed by lead migration (1.60%), fracture or failure of the lead or other parts of the implant (1.46% and 0.73%, resp.), IPG malfunctions (1.06%), and skin erosions without infections (0.48%). The authors also indicated that new indications for DBS, including Tourette’s syndrome, cluster headache, and refractory partial epilepsy, were found to pose a higher risk of hardware-related infections than established indications such as Parkinson’s disease [33]. In our series, slightly higher proportion (10%) of the patients suffered from the wound problems. But fortunately, most of the infections respond to antibiotherapy and/or surgical debridement. Only a fraction of these patients had intractable infection or inflammation that made removal of hardware components (mostly extension and IPG) inevitable. With the advent of new technologies, better surgical techniques, and prevention strategies [10, 34, 35], the rates of such serious wound complications have diminished considerably. Also, alternative medical and surgical strategies have been used to tackle these complications once occurred [36, 37].

Cumulative probability of hardware-related complications increases with longer follow-up durations [6, 38, 39]. In our series, we observed only two instances of lead malposition (1.1%), which represent a lower rate than that in most published series [7, 8, 16, 38, 40]. Of note, we confirm position of leads with routine immediate postoperative MRI and can check for lead migration using image fusion with CT scans during follow-up. On the contrary, fracture or disconnection of lead extensions, but not leads themselves, was more common in our series, possibly due to frequent traumatic incidents that those patients experienced. Replacement of lead extensions and IPG yielded good results in these patients.

Regarding the risk factors for surgical and hardware-related complications, many factors have been determined in previous studies such as advanced age, male sex, primary diagnosis, hypertension, obesity, and anemia [7, 12, 22]. In this series, we did not observe any effect of age, sex, or primary diagnosis on complication rates in line with findings of some other studies [14, 41]. In fact, the only factor we could determine to relate to complications was surgical experience [42, 43]. The fact that both multidisciplinary team dealing with and the protocols used for planning and execution of DBS implantation in our institute have remained unchanged for the past six years makes this series

---

**Figure 2:** Cumulative experience reduces the rate of complications following DBS surgery. The graph shows relatively constant annual caseload but remarkable reduction in the percentage of cases with complications throughout the years.
5. Conclusions

A wide range of complications and adverse events are associated with deep brain stimulation surgery. Neurosurgeons should inform patients about these potential problems and be prepared for them before, during, and after the surgery. Advances in our understanding, related technology, and surgical techniques have led to a dramatic decrease in the rates of these adverse events in the past two decades. Our study affirms the role of cumulative experience at individual centers in reducing the rate of complications. Further studies with larger cohorts are warranted to establish other risk factors and develop better strategies to tackle problems related to DBS surgery.

Data Availability

The data used to support the findings of this study are available from the corresponding author upon request.

Conflicts of Interest

The authors declare that there are no conflicts of interest regarding the publication of this article.

References

[1] A. L. Benabid, S. Chabardes, J. Mitrofanis, and P. Pollak, “Deep brain stimulation of the subthalamic nucleus for the treatment of Parkinson’s disease,” The Lancet Neurology, vol. 8, no. 1, pp. 67–81, 2009.

[2] S. Miocinovic, S. Somayajula, S. Chitnis, and J. L. Vitek, “History, applications, and mechanisms of deep brain stimulation,” JAMA Neurology, vol. 70, no. 2, pp. 163–171, 2013.

[3] G. Deuschl, C. Schade-Brittinger, P. Krack et al., “A randomized trial of deep-brain stimulation for Parkinson’s disease,” New England Journal of Medicine, vol. 355, no. 9, pp. 896–908, 2006.

[4] F. M. Weaver, K. Follett, M. Stern et al., “Bilateral deep brain stimulation vs best medical therapy for patients with advanced Parkinson disease: a randomized controlled trial,” JAMA, vol. 301, no. 1, pp. 63–73, 2009.

[5] N. R. Awan, A. Lozano, and C. Hamani, “Deep brain stimulation: current and future perspectives,” Neurosurgical Focus, vol. 27, no. 1, p. E2, 2009.

[6] J. Voges, Y. Waerzeggers, M. Maarouf et al., “Deep-brain stimulation: long-term analysis of complications caused by hardware and surgery—experiences from a single centre,” Journal of Neurology, Neurosurgery & Psychiatry, vol. 77, no. 7, pp. 868–872, 2006.

[7] J. P. Baizabal Carvallo, G. Mostile, M. Almaguer, A. Davidson, R. Simpson, and J. Jankovic, “Deep brain stimulation hardware complications in patients with movement disorders: risk factors and clinical correlations,” Stereotactic and Functional Neurosurgery, vol. 90, no. 5, pp. 300–306, 2012.

[8] A. J. Fenoy and R. K. Simpson Jr., “Risks of common complications in deep brain stimulation surgery: management and avoidance,” Journal of Neurosurgery, vol. 120, no. 1, pp. 132–139, 2014.

[9] D. M. Patel, H. C. Walker, R. Brooks, N. Omar, B. Ditty, and B. L. Guthrie, “Adverse events associated with deep brain stimulation for movement disorders: analysis of 510 consecutive cases,” Neurosurgery, vol. 11, no. 1, pp. 190–199, 2015.

[10] J. Zhang, T. Wang, C. C. Zhang et al., “The safety issues and hardware-related complications of deep brain stimulation therapy: a single-center retrospective analysis of 478 patients with Parkinson’s disease,” Clinical Interventions in Aging, vol. 12, pp. 923–928, 2017.

[11] J. Voges, R. Hilker, K. Bötzel et al., “Thirty days complication rate following surgery performed for deep-brain-stimulation,” Movement Disorders, vol. 22, no. 10, pp. 1486–1489, 2007.

[12] K. Hu, Z. B. Moses, M. M. Hutter, and Z. Williams, “Short-term adverse outcomes after deep brain stimulation treatment in patients with Parkinson disease,” World Neurosurgery, vol. 98, pp. 365–374, 2017.

[13] X. Hu, X. Jiang, X. Zhou et al., “Avoidance and management of surgical and hardware-related complications of deep brain stimulation,” Stereotactic and Functional Neurosurgery, vol. 88, no. 5, pp. 296–303, 2010.

[14] V. Levi, G. Carrabba, P. Rampini, and M. Locatelli, “Short term surgical complications after subthalamic deep brain stimulation for Parkinson’s disease: does old age matter?,” BMC Geriatrics, vol. 15, p. 116, 2015.

[15] E. J. Boviatis, L. C. Stavrinou, M. Themistocleous, A. T. Kouyialis, and D. E. Sakas, “Surgical and hardware complications of deep brain stimulation. A seven-year experience and review of the literature,” Acta Neurochirurgica, vol. 152, no. 12, pp. 2053–2062, 2010.

[16] P. K. Doshi, “Long-term surgical and hardware-related complications of deep brain stimulation,” Stereotactic and Functional Neurosurgery, vol. 89, no. 2, pp. 89–95, 2011.

[17] E. Coley, R. Farhadi, S. Lewis, and I. R. Whittle, “The incidence of seizures following deep brain stimulating electrode implantation for movement disorders, pain and psychiatric conditions,” British Journal of Neurosurgery, vol. 23, no. 2, pp. 179–183, 2009.

[18] N. Pouratian, D. L. Reames, R. Fryssinger, and W. J. Elias, “Comprehensive analysis of risk factors for seizures after deep brain stimulation surgery,” Journal of Neurosurgery, vol. 115, no. 2, pp. 310–315, 2011.

[19] F. Seijo, S. Alvarez de Eulate Beramendi, E. Santamarta Liébana et al., “Surgical adverse events of deep brain stimulation in the subthalamic nucleus of patients with Parkinson’s disease. The learning curve and the pitfalls,” Acta Neurochirurgica, vol. 156, no. 8, pp. 1505–1512, 2014.

[20] D. K. Binder, G. Rau, and P. A. Starr, “Hemorrhagic complications of microelectrode-guided deep brain stimulation,” Stereotactic and Functional Neurosurgery, vol. 80, no. 1–4, pp. 28–31, 2003.
[21] J. H. Park, S. J. Chung, C. S. Lee, and S. R. Jeon, “Analysis of hemorrhagic risk factors during deep brain stimulation surgery for movement disorders: comparison of the circumferential paired and multiple electrode insertion methods,” Acta Neurochirurgica, vol. 153, no. 8, pp. 1573–1578, 2011.

[22] C. A. Sansur, R. C. Frysinger, N. Pouratian et al., “Incidence of symptomatic hemorrhage after stereotactic electrode placement,” Journal of Neurosurgery, vol. 107, no. 5, pp. 998–1003, 2007.

[23] L. Zrinzo, T. Foltynie, P. Limousin, and M. I. Hariz, “Reducing hemorrhagic complications in functional neurosurgery: a large case series and systematic literature review,” Journal of Neurosurgery, vol. 116, no. 1, pp. 84–94, 2012.

[24] C. K. Park, N. Y. Jung, M. Kim, and J. W. Chang, “Analysis of delayed intracerebral hemorrhage associated with deep brain stimulation surgery,” World Neurosurgery, vol. 104, pp. 537–544, 2017.

[25] M. Tonge, L. Ackermans, E. Kocabicak et al., “A detailed analysis of intracerebral hemorrhages in DBS surgeries,” Clinical Neurology and Neurosurgery, vol. 139, pp. 183–187, 2015.

[26] G. Oyama, M. S. Okun, T. A. Zesiewicz et al., “Delayed clinical improvement after deep brain stimulation-related subdural hematoma. Report of 4 cases,” Journal of Neurosurgery, vol. 115, no. 2, pp. 289–294, 2011.

[27] T. Morishita, M. S. Okun, A. Burdick, C. E. Jacobson, and K. D. Foote, “Cerebral venous infarction: a potentially avoidable complication of deep brain stimulation surgery,” Neuroradiology: Technology at the Neural Interface, vol. 16, no. 5, pp. 407–413, 2013.

[28] M. Piacentino, G. Zambon, M. Pilleri, and L. Bartolomei, “Comparison of the incidence of intracranial hemorrhage in two different planning techniques for stereotactic electrode placement in the deep brain stimulation,” Journal of Neurosurgical Sciences, vol. 57, no. 1, pp. 63–67, 2013.

[29] S. Bériault, A. F. Sadikot, F. Alsubaie, S. Drouin, D. L. Collins, and G. B. Pike, “Neuronavigation using susceptibility-weighted venography: application to deep brain stimulation and comparison with gadolinium contrast,” Journal of Neurosurgery, vol. 121, no. 1, pp. 131–141, 2014.

[30] I. L. Maldonado, T. Roujeau, L. Cif et al., “Magnetic resonance-based deep brain stimulation technique: a series of 478 consecutive implanted electrodes with no perioperative intracerebral hemorrhage,” Operative Neurosurgery, vol. 65, no. S6, pp. 196–201, 2009.

[31] G. Fernández-Pajarín, A. Sesar, B. Ares et al., “Delayed complications of deep brain stimulation: 16-year experience in 249 patients,” Acta Neurochirurgica, vol. 159, no. 9, pp. 1713–1719, 2017.

[32] S. Bjerknes, I. M. Skogseid, T. Sæhle, E. Dietrichs, and M. Tøft, “Surgical site infections after deep brain stimulation surgery: frequency, characteristics and management in a 10-year period,” PLoS One, vol. 9, no. 8, Article ID e105288, 2014.

[33] O. Jitkritsadakul, R. Bhidayasiri, S. K. Kalia, M. Hodaie, A. M. Lozano, and A. Fasano, “Systematic review of hardware-related complications of deep brain stimulation: do new indications pose an increased risk?,” Brain Stimulation, vol. 10, no. 5, pp. 967–976, 2017.

[34] R. Bhatia, A. Dalton, M. Richards, C. Hopkins, T. Aziz, and D. Nandi, “The incidence of deep brain stimulator hardware infection: the effect of change in antibiotic prophylaxis regimen and review of the literature,” British Journal of Neurosurgery, vol. 25, no. 5, pp. 625–631, 2011.

[35] J. D. Hilliard, A. Bona, S. Vaziri, R. Walz, M. S. Okun, and K. D. Foote, “Delayed scalp erosion after deep brain stimulation surgery: incidence, treatment, outcomes, and prevention,” Neurosurgery, vol. 63, no. S1, p. 156, 2016.

[36] M. Lanotte, G. Verna, P. P. Panciani et al., “Management of skin erosion following deep brain stimulation,” Neurosurgical Review, vol. 32, no. 1, pp. 111–115, 2009.

[37] A. J. Fenoy and R. K. Simpson Jr., “Management of device-related wound complications in deep brain stimulation surgery,” Journal of Neurosurgery, vol. 116, no. 6, pp. 1324–1332, 2012.

[38] M. Y. Oh, A. Abosch, S. H. Kim, A. E. Lang, and A. M. Lozano, “Long-term hardware-related complications of deep brain stimulation,” Neurosurgery, vol. 50, no. 6, pp. 1268–1274, 2002.

[39] K. E. Lyons, S. B. Wilkinson, J. Overman, and R. Pahwa, “Surgical and hardware complications of subthalamic stimulation: a series of 160 procedures,” Neurology, vol. 63, no. 4, pp. 612–616, 2004.

[40] C. Hamani and A. M. Lozano, “Hardware-related complications of deep brain stimulation: a review of the published literature,” Stereotactic and Functional Neurosurgery, vol. 84, no. 5–6, pp. 248–251, 2006.

[41] M. R. DeLong, K. T. Huang, J. Gallis et al., “Effect of advancing age on outcomes of deep brain stimulation for Parkinson disease,” JAMA Neurology, vol. 71, no. 10, pp. 1290–1295, 2014.

[42] S. Bhatia, M. Oh, T. Whiting, M. Quigley, and D. Whiting, “Surgical complications of deep brain stimulation. A longitudinal single surgeon, single institution study,” Stereotactic and Functional Neurosurgery, vol. 86, no. 6, pp. 367–372, 2008.

[43] S. M. Falowski, Y. C. Ooi, and R. A. Bakay, “Long-term evaluation of changes in operative technique and hardware-related complications with deep brain stimulation,” Neurosurgical Review, vol. 31, no. 8, pp. 670–677, 2015.

[44] J. F. Baizabal Carvallo, R. Simpson, and J. Jankovic, “Diagnosis and treatment of complications related to deep brain stimulation hardware,” Movement Disorders, vol. 26, no. 8, pp. 1398–1406, 2011.